首页> 外文期刊>Journal of the American Chemical Society >Probing the Structural Requirements of Peptoids That Inhibit HDM2-p53 Interactions
【24h】

Probing the Structural Requirements of Peptoids That Inhibit HDM2-p53 Interactions

机译:探索抑制HDM2-p53相互作用的类肽的结构要求

获取原文
获取原文并翻译 | 示例
           

摘要

Many cellular processes are controlled by protein-protein interactions,and selective inhibition of these interactions could lead to the development of new therapies for several diseases.In the area of cancer,overexpression of the protein,human double minute 2 (HDM2),which binds to and inactivates the protein p53,has been linked to tumor aggressiveness and drug resistance.In general,inhibition of protein-protein interactions with synthetic molecules is challenging and currently remains a largely uncharted area for drug development.One strategy to create inhibitors of protein-protein interactions is to recreate the three-dimensional arrangement of side chains that are involved in the binding of one protein to another,using a nonnatural scaffold as the attachment point for the side chains.In this study,we used oligomeric peptoids as the scaffold to begin to develop a general strategy in which we could rationally design synthetic molecules that can be optimized for inhibition of protein-protein interactions.Structural information on the HDM2-p53 complex was used to design our first class of peptoid inhibitors,and we provide here,in detail,the strategy to modify peptoids with the appropriate side chains that are effective inhibitors of HDM2-p53 binding.While we initially tried to develop rigid,helical peptoids as HDM2 binders,the best inhibitors were surprisingly peptoids that lacked any helix-promoting groups.These results indicate that starting with rigid peptoid scaffolds may not always be optimal to develop new inhibitors.
机译:许多细胞过程受蛋白质-蛋白质相互作用的控制,选择性抑制这些相互作用可能导致开发出针对多种疾病的新疗法。在癌症领域,蛋白质的过度表达与人类双分钟2(HDM2)结合蛋白p53的失活与肿瘤的侵袭性和耐药性有关。总的来说,抑制蛋白与合成分子的相互作用具有挑战性,目前仍是药物开发领域中一个未知领域。蛋白质相互作用是通过使用非天然支架作为侧链的连接点,重现涉及一种蛋白质与另一种蛋白质结合的侧链的三维排列。在本研究中,我们使用低聚类肽作为支架开始制定一种总体策略,在该策略中,我们可以合理设计可以优化用于抑制蛋白-pr的合成分子使用关于HDM2-p53复合物的结构信息来设计我们的第一类类肽抑制剂,并且在此我们详细提供了使用适当的侧链修饰类肽的策略,所述侧链是有效的HDM2-p53结合抑制剂。当我们最初尝试开发刚性,螺旋状拟肽作为HDM2结合剂时,最好的抑制剂是令人惊讶的缺乏任何螺旋促进基团的拟肽。这些结果表明,从刚性拟肽支架开始可能不一定总是开发新抑制剂的最佳选择。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2006年第6期|p.1995-2004|共10页
  • 作者单位

    Contribution from the Laboratory of Cell Biology,NCI,National Institutes of Health,DHHS, Bethesda,Maryland 20892,Department of Chemistry,Northwestern University, Evanston,Illinois 60208,and Laboratory of Bioorganic Chemistry,NIDDK, National Institute;

    Contribution from the Laboratory of Cell Biology,NCI,National Institutes of Health,DHHS, Bethesda,Maryland 20892,Department of Chemistry,Northwestern University, Evanston,Illinois 60208,and Laboratory of Bioorganic Chemistry,NIDDK, National Institute;

    Contribution from the Laboratory of Cell Biology,NCI,National Institutes of Health,DHHS, Bethesda,Maryland 20892,Department of Chemistry,Northwestern University, Evanston,Illinois 60208,and Laboratory of Bioorganic Chemistry,NIDDK, National Institute;

    Contribution from the Laboratory of Cell Biology,NCI,National Institutes of Health,DHHS, Bethesda,Maryland 20892,Department of Chemistry,Northwestern University, Evanston,Illinois 60208,and Laboratory of Bioorganic Chemistry,NIDDK, National Institute;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号